Short Summary
This was a patent infringement suit filed by Astrazeneca AB and another plaintiff against MSN Laboratories Private Limited seeking a permanent injunction restraining the defendant from infringing Indian Patent Nos. 205147 and 235625. During the pendency of the suit, the parties amicably settled their disputes and entered into a confidential Settlement Agreement. The court allowed the joint application, recorded the settlement, decreed the suit in terms of the settlement, and granted the plaintiffs a refund of the entire court fees.
Detailed Summary
The suit, CS(COMM) 426/2020, was instituted before the Delhi High Court by Astrazeneca AB and another plaintiff (represented by Ms. Vaishali Mittal and Mr. Shivang Sharma, Advocates) against MSN Laboratories Private Limited (represented by Mr. Rahul Bhujbal, Advocate). The plaintiffs sought a permanent injunction restraining the defendant and all others acting on its behalf from infringing Indian Patent Nos. 205147 and 235625.
The dispute centered on the alleged infringement of two Indian patents held by the plaintiffs. The plaintiffs sought permanent injunctive relief to prevent the defendant from infringing these patents. However, during the pendency of the suit, the parties amicably resolved their disputes and entered into a Settlement Agreement, the terms of which were stated to be confidential in nature. As a result of the settlement, the parties agreed to dispose of the suit and discharge each other from any and all claims, demands, costs, damages, and causes of action arising from the subject matter of the suit.
The court, presided over by Hon'ble Ms. Justice Jyoti Singh, considered the joint application filed by both parties under Order XXIII Rule 3 read with Section 151 of the CPC for recording the settlement and withdrawal of the suit. The court allowed the application and recorded the settlement between the parties. The suit was decreed in terms of the Settlement Agreement, with the agreement forming part of the decree and binding the parties thereto. The parties were discharged of their respective liabilities, claims, and demands arising from the subject matter of the suit. The registry was directed to draw up the decree sheet, and the suit along with pending applications was disposed of. The plaintiffs were held entitled to a refund of the entire court fees in accordance with the Court Fees Act, 1870. The previously scheduled date of 28.09.2026 was cancelled.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in AstraZeneca AB & Anr. vs MSN Laboratories Private Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Tata Sons LimitedvsRam Niwas & Ors
The Delhi High Court ruled in favor of Tata Sons Limited, granting permanent injunctions against Ram Niwas & Ors for trademark infringement and passing off. The court found that the defendants were deceptively using the mark 'TATA' and the domain name 'www.tatapackers.com' to associate themselves with the well-known TATA brand in the transport and logistics sector. Furthermore, the defendants were ordered to transfer the infringing domain name to Tata Sons Limited.
Nike Innovate C.V.vsMr. Anwar Ali
The plaintiff, Nike Innovate C.V., filed a suit alleging that the defendant was manufacturing, stocking, distributing, and selling infringing shoes and accessories bearing identical or deceptively similar 'Nike' trademarks and logos in Delhi. The court found that the defendant was causing confusion and deception among the public by using falsified marks on inferior quality goods.
Dr. Sapna NangiavsThe Assistant Controller of Patents and Designs
Dr. Sapna Nangia filed an appeal challenging the Assistant Controller of Patents and Designs' order dated January 29, 2021. The original patent application (No. 201911010599) for a device and process was rejected primarily on the ground of lacking inventive step.
Novartis AgvsMedipol Pharmaceuticals India Pvt Ltd
The plaintiff, Novartis Ag, filed a suit alleging infringement of its patent (IN 233161) concerning the drug Eltrombopag Olamine. The court found a clear prima facie case in favor of the plaintiff, noting that the rights to the patent had been confirmed previously.
Sun Pharmaceutical Industries LimitedvsMackedos Pharmaceuticals Ltd.
In this trademark infringement suit, Sun Pharmaceutical Industries Limited sought a permanent injunction against Mackedos Pharmaceuticals Ltd. regarding the use of the mark 'OFLOMAC.' The court noted that the matter was previously stayed pending an IPAB order which ultimately favored the Plaintiff by ordering the removal of the Defendant's mark due to deceptive similarity with 'OFRAMAX.' However, given conflicting statements made by counsel before the Bombay High Court regarding the continuation of the suit, the Delhi High Court decided not to rule on the procedural dispute and instead issued notice for the Defendant to file a reply.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.